NEW YORK, NY–(Marketwired – Jun 4, 2014) – PharmaCyte Biotech, Inc. (OTCQB: NVLX) President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company’s pancreatic cancer treatment in an interview with Stock Market Media Group, a research and content development investment relations firm, while the two were attending the American Society of Clinical Oncology (ASCO) conference in Chicago from Friday May 30 to Tuesday June 3.
Listen to the interview at: www.stockmarketmediagroup.com/media
In the interview, both the CEO and COO discussed when the company expects to begin its upcoming Phase 2b clinical trial in advanced pancreatic cancer with Clinical Network Services (CNS) and the company’s preclinical studies treating the symptoms associated with pancreatic cancer to be conducted by Translational Drug Development (TD2).
PharmaCyte Biotech’s shareholders should draw great confidence from the interview when they learn where the idea was born to conduct preclinical and clinical trials on symptoms associated with pancreatic cancer, and from a CEO who’s on a mission to bring a better treatment to patients suffering from the deadly cancer after his own father died of the disease.
The company’s executives also talked about obtaining Orphan Drug Status for its pancreatic cancer treatment that uses the Cell-in-a-Box® technology combined with the anticancer drug ifosfamide, the new $50 million banking agreement with Chardan Capital Markets, and much more related to PharmaCyte Biotech’s efforts to get its pancreatic cancer treatment to market.
Listen to the interview at: www.stockmarketmediagroup.com/media
About Stock Market Media Group
SMMG is a Research and Content Development IR firm offering a platform for corporate stories to unfold in the media with Reports, Interviews and Articles. SMMG is compensated for PharmaCyte Biotech content by a third party who reserves the right to buy, sell or remain neutral on securities after the publication of this article. SMMG has received total compensation of $93,960 for content related to PharmaCyte Biotech. Additionally, a principal at SMMG currently owns 200,000 total shares of PharmaCyte Biotech issued by the company through a consulting agreement which has since ended for work unrelated to content development. All shares have been held for the requisite period under Rule 144 as of April 30, 2014, and are eligible to be sold immediately without further notice. For more information: www.stockmarketmediagroup.com.
Contact:
Stock Market Media Group
Email Contact
